DF/Net has been working with IDRI on Leishmaniasis vaccine studies since 2006. Leishmaniasis is a parasitic disease that occurs in 88 countries around the world. It has an estimated annual incidence of two million cases and a prevalence of 12 million cases. Visceral leishmaniasis, the most severe form of the disease, affects vital organs and has a high fatality rate if not treated. Cutaneous leishmaniasis, the most common form of the disease, causes serious skin lesions and often leaves its victims permanently disfigured. Drugs to treat leishmaniasis are expensive, toxic, or impractical.
IDRI is actively developing vaccines for human and canine leishmaniasis. The human vaccine is being evaluated for prophylactic and therapeutic indications in clinical trials in South America, India and Sudan. The canine vaccine is being tested in Brazil, where dogs are an important source of human infection. To date, these studies have shown that the vaccines are safe, well tolerated, immunogenic, and potentially efficacious in the prevention and treatment of diverse forms of leishmaniasis.
DF/Net has provided data management for IDRI’s vaccine programs in Colombia, Venezuela, Brazil, Peru, Sudan, and India, as well as its flu program more close to home in Texas, Florida, and Wisconsin.
Jill Ashman, Associate Director Clinical Operations for IDRI said of DF/Net:
“The team at DF/Net are a pleasure to work with. They provide excellent service and are always quick to respond. Conducting studies on four continents, often in remote settings, is a challenge and DF/Net has been able to help IDRI with solutions that work. The ability to connect to their system using iDataFax and view study data in real time is crucial to our research.”